文献速递慢性静脉疾病

血流动力学混合Nd:YAG 1064激光与冷冻硬化治疗C1和C2患者的疗效与安全性

Safety and efficacy for the treatment of C1 and C2 patients with a new method hemodynamic hybrid Nd YAG 1064 LASER and cryosclerotherapy.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2025-09-30

这项回顾性队列纳入41例C1和C2低级别慢性静脉疾病女性患者,评估血流动力学混合YAG激光与冷却67%–75%葡萄糖注射冷冻硬化治疗的安全性和有效性。共完成71次治疗,83%(34/41)患者达到完全清除,最常见并发症为炎症后色素沉着,无皮肤坏死,出现2例轻微血栓事件。结论认为该门诊治疗方案安全有效,可能减少早期慢性静脉疾病对侵入性大隐静脉手术的需求。

要点

  • 41例C1/C2女性患者共71次治疗,83%达到完全清除。
  • 炎症后色素沉着最常见,无皮肤坏死,2例轻微血栓事件。
  • 该门诊方案可能减少早期慢性静脉疾病对侵入性手术的需求。

核心结论

  • 血流动力学混合激光冷冻硬化治疗对C1和C2低级别患者似乎是安全有效的门诊治疗方案。
  • 该治疗可能减少早期慢性静脉疾病对侵入性大隐静脉手术的需求。

研究设计与样本

  • 共纳入41例女性,所有患者接受临床评估、多普勒超声静脉映射及标准化治疗前后摄影。
  • 排除标准包括既往大隐静脉治疗、血栓栓塞事件和Fitzpatrick皮肤VI型。
  • 治疗采用YAG激光与冷却的67%至75%葡萄糖注射。

主要发现

  • 共完成71次治疗。
  • 基于治疗医师与患者共识的摄影比较,83%(34/41)患者达到完全清除。
  • 炎症后色素沉着是最常见并发症,无皮肤坏死病例。
  • 观察到2例轻微血栓事件,无过敏反应报告。

关键数值与推荐

  • 病变清除分为清除不足(<50%)、中度(50%-69%)和完全(70%-100%)。
  • 完全清除率为83%(34/41)。

临床怎么用

  • 对于C1和C2低级别慢性静脉疾病患者,可考虑采用血流动力学混合激光冷冻硬化治疗作为门诊治疗选择。
  • 治疗前应进行临床评估和多普勒超声静脉映射,并排除既往大隐静脉治疗、血栓栓塞事件及Fitzpatrick皮肤VI型患者。
  • 治疗后需关注炎症后色素沉着和血栓事件等并发症。

局限性

  • 本研究为回顾性队列研究,样本量较小(41例女性)。
  • 清除率评估基于治疗医师与患者共识的摄影比较,可能存在主观性。
  • 研究仅纳入女性患者,结果可能不适用于男性人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and efficacy of hemodynamic hybrid LASER cryosclerotherapy for the treatment of chronic venous disease in patients with telangiectasias, reticular veins, and varicose veins. METHODS: This retrospective cohort included patients classified as C1 and C2 low treated between February 2022 and November 2024. A total of 41 women were included. All patients underwent clinical evaluation, Doppler ultrasound venous mapping for evidence of deep and superficial reflux and standardized pretreatment and post-treatment photography. Exclusion criteria included previous saphenous treatment, thromboembolic events, and Fitzpatrick skin type VI. We used YAG Laser and cooled 67% to 75% dextrose injection. RESULTS: A total of 71 treatment sessions were performed. Lesion clearance was categorized as insufficient (<50%), moderate (50%-69%), or complete (70%-100%) based on photographic comparison by the treating physician and patient consensus. Complete clearance was achieved in 83% of patients (34/41). Postinflammatory hyperpigmentation was the most common complication, with no cases of skin necrosis. Two minor thrombotic events were observed. No allergic reactions were reported. CONCLUSIONS: Hemodynamic hybrid LASER cryosclerotherapy appears to be a safe and effective office-based treatment for C1 and C2 low patients, potentially reducing the need for invasive saphenous vein procedures in early-stage chronic venous disease.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Sathler de Melo CC, Faccini FP. Safety and efficacy for the treatment of C1 and C2 patients with a new method hemodynamic hybrid Nd YAG 1064 LASER and cryosclerotherapy. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 41038570. doi:10.1016/j.jvsv.2025.102320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。